Please assess the completion status of the following clinical trial:

Trial Title: Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary or recurrent disease~* Histological confirmation of primary (or recurrent) and metastatic disease~* Systemic chemotherapy and/or biological is allowed before and/or after CRS+HIPC~* Radiotherapy is allowed before or after CRS+HIPC~* Patients must not have failed prior intraperitoneal platinum-therapy~* Age between 18 to 75 years~* Patient Karnofsky performance scale (KPS) \> 80 (normal activity with a bit of effort)~Exclusion Criteria:~* Age \< 18 or \> 75 years~* Pregnancy~* Any malignancy other than biliary, gastric, or pancreatic adenocarcinoma~* Any metastatic disease outside the abdominal compartment, such as pulmonary or bone metastases~* Peritoneal carcinomatosis index (PCI) \> 20 at the start of CRS~* Peritoneal residual tumour nodules larger than 2.5 mm after CRS (CCR-2)~* Clinical relevant ascites~* More than 3 liver metastases~* Solitary liver metastasis larger than 5 cm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CRS+HIPC (Type: EXPERIMENTAL): Patients with biliary, gastric, or pancreatic carcinoma and metastatic or recurrent disease confined to the abdominal compartment

Based on this trial design, predict the completion outcome and termination type (if applicable).